Lupus erythematosus
☆ Natiijooyinka Stiftung Warentest ee 2022 ee ka yimid Jarmalka, ku qanacsanaanta macaamilka ee ModelDerm ayaa waxyar uun ka hooseysay la-talinta telemedicine-ka ee lacagta lagu bixiyo.
Waxay u muuqataa sida cuncun yar oo guduudan.
Finanka balanbaalista ee sida caadiga ah ka soo baxa wejiga.
References
Aqoonsiga iyo kala soocida cutaneous lupus erythematosus (CLE) waxay keenaysaa caqabadaha ogaanshaha, iyada oo laga soocay systemic lupus erythematosus ku lug lahaanshaha maqaarka. Daraasadihii ugu dambeeyay waxay iftiimiyeen arrimaha hidda-socodka, deegaanka, iyo difaaca jirka ee ka hooseeya CLE. Daroogadu waxay si gaar ah u soo baxday mid ka mid ah kiciyeyaasha ugu muhiimsan ee CLE. Daaweyntu waxay ku lug leedahay daawayn jirka la mariyo iyo habaysan, oo ay ku jiraan bayooloji rajo leh (belimumab, rituximab, ustekinumab, anifrolumab, BIIB059) , oo leh waxtarka la muujiyay ee tijaabooyinka kiliinikada.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Cutaneous lupus erythematosus (CLE) waxay dabooshaa arrimo maqaarka oo kala duwan, kuwaas oo qaarkood laga yaabo inay la xiriiraan dhibaatooyin caafimaad oo ballaaran. Waxaa loo kala saaraa noocyo kala duwan, sida acute CLE (ACLE) , sub-acute CLE (SCLE) , and chronic CLE (CCLE) . CCLE waxay ka kooban tahay discoid lupus erythematosus (DLE) , LE profundus (LEP) , chilblain cutaneous lupus, and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Lupus erythematosus waa koox ka mid ah cudurrada difaaca jirka oo saameeya qaybaha kala duwan ee jirka. Noocyada qaarkood, sida systemic lupus erythematosus (SLE) , waxay saameeyaan xubno badan, halka kuwa kale, sida cutaneous lupus erythematosus (CLE) , ay inta badan saameeyaan maqaarka. Waxaan u kala saarnaa noocyada kala duwan ee CLE iyadoo lagu salaynayo isku dhafka calaamadaha bukaan-socodka, baaritaanka unugyada, iyo baaritaanka dhiigga, laakiin waxaa jira kala duwanaansho badan oo u dhexeeya shakhsiyaadka. Dhibaatooyinka maqaarka inta badan waxay ku dhacaan arrimo ay ka mid yihiin soo-gaadhista iftiinka qorraxda, sigaarka, ama daawooyinka qaarkood.
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Sababta lupus erythematosus ma cadda. Mataanaha isku midka ah, haddii mid la saameeyo waxaa jirta fursad 24% ka kale sidoo kale waa uu ahaan doonaa. Hormoonnada galmada dheddigga, iftiinka qorraxda, sigaarka, yaraanta fitamiin D-ga, iyo cudurrada qaarkood ayaa sidoo kale la rumeysan yahay inay kordhiyaan khatarta.
Daawaynta waxaa ku jiri kara NSAIDs, corticosteroids, immunosuppressants, hydroxychloroquine, iyo methotrexate. Inkasta oo corticosteroids ay waxtar leeyihiin, isticmaalka muddada dheer waxay keenaysaa saameyno.